UK health regulator may restrict AstraZeneca shot for younger people, Channel 4 says
Reuters
Published Apr 05, 2021 19:32
Updated Apr 05, 2021 21:30
LONDON (Reuters) -Britain's health regulator is considering a proposal to restrict the use of the Oxford-AstraZeneca vaccine in younger people over concerns about very rare blood clots, Channel 4 News reported on Monday.
"Two senior sources have told this programme that while the data is still unclear, there are growing arguments to justify offering younger people - below the age of 30 at the very least - a different vaccine," the broadcaster reported.
The UK's regulator, the MHRA, said later on Monday that no decision had been taken.
It previously said the benefits of the vaccine in the prevention of COVID-19 far outweighed any possible risk of blood clots and that people should continue to get their vaccine when invited to do so.
"Our thorough and detailed review is ongoing into reports of very rare and specific types of blood clots with low platelets following the COVID-19 Vaccine AstraZeneca (NASDAQ:AZN)," Medicines and Healthcare Products Regulatory Agency Chief Executive June Raine said. "No decision has yet been made on any regulatory action."
Britain has managed one of the fastest vaccine rollouts in the world, with 36 million people receiving a first or second shot. It started providing vaccines to its oldest citizens first, along with healthcare workers and the clinically vulnerable.
Get The App
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.